Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00385827 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
A Phase 2 study, sponsored by Centocor.
- Terminated
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
NCT00385827 is a Phase 2 study that was terminated before completion, run by Centocor. The registered enrollment target is 106 participants.
The verdict
NCT00385827, a Phase 2 study, was terminated before completion, sponsored by Centocor.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of siltuximab administered in combination with mitoxantrone and prednisone in participants with metastatic (spread of cancer cells from one part of the body to another) hormone-refractory (not responding to treatment) prostate cancer (abnormal tissue that grows and spreads in the body) (HRPC).
Interventions
- DRUG Prednisone
- DRUG Siltuximab
- DRUG Mitoxantrone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00385827
The ClinicalTrials.gov registry entry for NCT00385827 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prednisone is the first listed.
NCT00385827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00385827 about?
NCT00385827 is a clinical study titled "A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)". The purpose of this study is to assess the safety and efficacy of siltuximab administered in combination with mitoxantrone and prednisone in participants with metastatic (spread of cancer cells from one part of the body to another) hormone-refractory (not responding to treatment) prostate cancer (ab...
What is the current status of trial NCT00385827?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2006-11. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00385827?
The interventions under investigation include: Prednisone (DRUG), Siltuximab (DRUG), Mitoxantrone (DRUG).
Who is sponsoring clinical trial NCT00385827?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.